openPR Logo
Press release

Congenital Hyperinsulinism Market Expected to Experience Major Growth by 2034, According to DelveInsight | Zealand Pharma, Rezolute, Eiger BioPharma, Crinetics, AmideBio, Hanmi pharmaceutical

07-18-2025 02:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Congenital Hyperinsulinism Market Expected to Experience

The Key Congenital Hyperinsulinism Companies in the market include - Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical, and others.

DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Congenital Hyperinsulinism, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Congenital Hyperinsulinism market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Congenital Hyperinsulinism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Hyperinsulinism Market Insights [https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Congenital Hyperinsulinism Market Report:

*
The Congenital Hyperinsulinism market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In January 2025, Rezolute, an affiliate of Handok, announced that the FDA has granted Breakthrough Therapy Designation to RZ358 (ersodetug) for treating hypoglycemia associated with congenital hyperinsulinism.

*
In December 2024, Sidra Medicine, a member of Qatar Foundation, has conducted the industry-sponsored 'sunRIZE' trial focused on pediatric congenital hyperinsulinism. This marks the first pharmaceutical trial following the launch of Sidra's 'Clinical Trials Program,' which aims to enhance treatment options for rare and complex diseases in the Arab region. The Phase III sunRIZE trial is being led by biopharmaceutical company Rezolute.

*
In October 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of its New Drug Application (NDA) for dasiglucagon. The application sought approval for dasiglucagon to prevent and treat hypoglycemia in pediatric patients aged seven days and older with congenital hyperinsulinism (CHI) for up to three weeks of dosing.

*
DelveInsight's estimates indicate that in 2023, the diagnosed prevalent cases of Congenital HyperInsulinism in the United States accounted for around 20% of the total cases across the 7MM.

*
According to DelveInsight's consultant estimates, the diffuse type accounted for the majority of Congenital HyperInsulinism (CHI) cases, comprising approximately 75% of CHI cases in the United States in 2023.

*
Mutation-specific prevalence analysis indicates that ABCC8 and KCNJ11 mutations are more frequently observed in CHI patients compared to other mutations.

*
Zealand Pharma plans to resubmit its New Drug Application (NDA) to the FDA in early 2024 for ZEGALOGUE (dasiglucagon), which is being evaluated for treating pediatric hypoglycemia in congenital hyperinsulinism (CHI) patients. This follows a 2023 Complete Response Letter addressing concerns related to the manufacturing facility.

*
Key Congenital Hyperinsulinism Companies: Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical, and others

*
Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

*
The Congenital Hyperinsulinism epidemiology based on mutation specific cases analyzed that mutation in ABCC8 and KCNJ11 genes are more common than other mutations of Congenital Hyperinsulinism in the 7MM

Congenital Hyperinsulinism Overview

Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

Get a Free sample for the Congenital Hyperinsulinism Market Report:

https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market [https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Hyperinsulinism Market

The dynamics of the Congenital Hyperinsulinism market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2020-2034.

"Congenital Hyperinsulinism (CHI) pipeline is not robust, however it possess promising and potential drugs in clinical stage of developments, which are expected to be launched in the near future. Dasiglucagon is currently in the Phase III stage of development followed by RZ358 and Avexitide that are in Phase II clinical development stage. Out of these therapies, RZ358 has already completed a Phase II clinical developmental trial."

Congenital Hyperinsulinism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congenital Hyperinsulinism Epidemiology Segmentation:

The Congenital Hyperinsulinism market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Congenital Hyperinsulinism

*
Prevalent Cases of Congenital Hyperinsulinism by severity

*
Gender-specific Prevalence of Congenital Hyperinsulinism

*
Diagnosed Cases of Episodic and Chronic Congenital Hyperinsulinism

Download the report to understand which factors are driving Congenital Hyperinsulinism epidemiology trends @ Congenital Hyperinsulinism Epidemiological Insights [https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Hyperinsulinism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Hyperinsulinism market or expected to get launched during the study period. The analysis covers Congenital Hyperinsulinism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Hyperinsulinism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Hyperinsulinism Therapies and Key Companies

*
Dasiglucagon: Zealand Pharma

*
RZ358: Rezolute

*
Avexitide: Eiger BioPharmaceuticals

*
CRN04777: Crinetics

*
ABG-023: AmideBio

*
HM15136: Hanmi pharmaceutical

To know more about Congenital Hyperinsulinism treatment, visit @ Congenital Hyperinsulinism Medications [https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Hyperinsulinism Market Drivers

*
The Congenital Hyperinsulinism emerging pipeline holds the pioneering therapies in competition due to the presence of only one approved therapy, which provides an upper hand for initiating research and development in this area

*
One of the major strengths of this market is the increasing research, awareness and support for the disease will drive the market in the long run

Congenital Hyperinsulinism Market Barriers

*
The major weakness of the market is the fact that Congenital Hyperinsulinism can relapse in some cases

*
There is a significant lack of proper diagnosis and management of Congenital Hyperinsulinism, which clearly depicts that the management and diagnosis paradigm of Congenital Hyperinsulinism is to date under studied and needs to be updated

Scope of the Congenital Hyperinsulinism Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Congenital Hyperinsulinism Companies: Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical

*
Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

*
Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies

*
Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Congenital Hyperinsulinism Unmet Needs, KOL's views, Analyst's views, Congenital Hyperinsulinism Market Access and Reimbursement

Discover more about therapies set to grab major Congenital Hyperinsulinism market share @ Congenital Hyperinsulinism Treatment Market [https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Congenital Hyperinsulinism Market Report Introduction

2. Executive Summary for Congenital Hyperinsulinism

3. SWOT analysis of Congenital Hyperinsulinism

4. Congenital Hyperinsulinism Patient Share (%) Overview at a Glance

5. Congenital Hyperinsulinism Market Overview at a Glance

6. Congenital Hyperinsulinism Disease Background and Overview

7. Congenital Hyperinsulinism Epidemiology and Patient Population

8. Country-Specific Patient Population of Congenital Hyperinsulinism

9. Congenital Hyperinsulinism Current Treatment and Medical Practices

10. Congenital Hyperinsulinism Unmet Needs

11. Congenital Hyperinsulinism Emerging Therapies

12. Congenital Hyperinsulinism Market Outlook

13. Country-Wise Congenital Hyperinsulinism Market Analysis (2020-2034)

14. Congenital Hyperinsulinism Market Access and Reimbursement of Therapies

15. Congenital Hyperinsulinism Market Drivers

16. Congenital Hyperinsulinism Market Barriers

17. Congenital Hyperinsulinism Appendix

18. Congenital Hyperinsulinism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=congenital-hyperinsulinism-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-zealand-pharma-rezolute-eiger-biopharma-crinetics-amidebio-hanmi-pharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Congenital Hyperinsulinism Market Expected to Experience Major Growth by 2034, According to DelveInsight | Zealand Pharma, Rezolute, Eiger BioPharma, Crinetics, AmideBio, Hanmi pharmaceutical here

News-ID: 4110112 • Views:

More Releases from ABNewswire

PMHScribe Unveils AI-Charting Technology for Psychiatry in Partnership wIth FastTrack CEO
PMHScribe Unveils AI-Charting Technology for Psychiatry in Partnership wIth Fast …
Cutting-edge scribe technology decreases the time medical practitioners spend charting. Winston-Salem - July 26th, 2025 - PMHScribe recently launched an automated note-taking and charting software in partnership with FastTrack CEO to streamline psychiatric documentation for practitioners and patients. PMHScribe is rapidly increasing in customer count as it expands its platform. PMHScribe captures audio during clinical sessions and converts it into fully formatted chart notes using methods that ensure the patient's safety and
Cheapest 2025 Denver Broncos Ticket Deals: Use CITY10 Promo Code at CapitalCityTickets.com - All Seating on Sale for Home and Away Games
Cheapest 2025 Denver Broncos Ticket Deals: Use CITY10 Promo Code at CapitalCityT …
Find the cheapest 2025 Denver Broncos ticket deals at CapitalCityTickets.com. Use promo code CITY10 to save extra on all seating options for both home and away games. Whether you want premium seats or budget-friendly options, CapitalCityTickets.com has you covered. Don't miss out on NFL action-secure your tickets early, save big, and cheer on the Broncos live all season long! Get ready to cheer on the Denver Broncos at Empower Field at
From Ashes to Light: Masterpieces Reborn
From Ashes to Light: Masterpieces Reborn
In 2024, renowned Japanese printmaker Kouji Ochiai passed away in a sudden fire, leaving nearly 1,000 hidden works. His son, Yosuke Gifre Ochiai, now seeks to preserve and share these masterpieces through a Kickstarter campaign-honoring his father's legacy while transforming the forgotten studio into a space of healing and inspiration for future generations. A Lost Father. A Discovered Legacy. The Life and Prints of Kouji Ochiai [https://www.kickstarter.com/projects/1561310332/from-flames-my-fathers-paintings-whisper-through-time] , Brought to the World
Arlington-Based Realtor Eric Torres Redefines the Home Buying Experience for First-Time Buyers and Sellers in DFW Metroplex
Arlington-Based Realtor Eric Torres Redefines the Home Buying Experience for Fir …
In the fast-paced world of real estate, Eric Torres, a licensed Realtor based in Arlington, TX, is setting new standards for how first-time homebuyers and sellers navigate one of life's most significant decisions. Serving the DFW Metroplex, including Fort Worth, Mansfield, Grand Prairie, and Bedford, Torres is committed to providing personalized service that paves the way for seamless transactions. Image: https://www.abnewswire.com/upload/2025/07/16e26585eea91e5dd0518a3687add09a.PNG Understanding first-time buyers' challenges, Torres champions an approach centered on clear

All 5 Releases


More Releases for Congenital

Maternal Diabetes Driving Congenital Heart Disease Market Growth: A Significant …
The Congenital Heart Disease (CHD) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Congenital Heart Disease (CHD) Market Size and Projected Growth Rate? The congenital heart disease (CHD) market will increase from $4.42 billion in 2024 to $4.87 billion in 2025, growing at
Leading Growth Driver in the Congenital Heart Disease (CHD) Market in 2025: Mate …
What Are the Market Size and Growth Forecast for the Congenital Heart Disease (CHD) Market? The market size for congenital heart disease (CHD) has seen a rapid expansion in the recent years. It's projected to increase from $4.42 billion in 2024 to $4.87 billion in 2025, marking a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the growth during the historical period include a rise in risk factors like
Congenital Diarrheal Disorders Market Outlook Report 2032 by DelveInsight
DelveInsight's "Congenital Diarrheal Disorders Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Congenital Diarrheal Disorders, historical and forecasted epidemiology as well as the Congenital Diarrheal Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Congenital Diarrheal Disorders market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
Understanding the Congenital Hyperinsulinism Market: Size, Trends, and Insights
Congenital Hyperinsulinism (CHI) is an exceedingly rare genetic disorder that impacts individuals from birth. It is characterized by the overproduction of insulin by the pancreas, leading to persistent and severe hypoglycemia. The CHI market is of significant importance not only for healthcare professionals but also for affected individuals and their families. This article provides a detailed analysis of the CHI market, covering aspects such as market size, trends, segmentation, and
Leber Congenital Amaurosis Market by Players and Application 2024
Leber Congenital Amaurosis Market: Overview Leber congenital amaurosis (LCA) is a disorder of eye mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for detection of light and color. People, primarily babies suffering with this disorder have severe visual impairment from the first year of life. The visual impairment because of this disorder likely to be stable for the rest of the life, whereas
Congenital Heart Disease-Pipeline Insights, 2017
Orbis Research released a new research report of 60 pages on title “Congenital Heart Disease-Pipeline Insights, 2017” Report Focuses on Market, Status and Forecast, by Players, Types and Applications’ with detailed analysis, forecast and strategies. “Congenital Heart Disease-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Congenital Heart Disease. The Report covers the product profiles in various stages of development including